The Blood and Marrow Transplant Program at Northside Hospital (NH-BMT) provides the best of both worlds—clinical excellence and compassionate care. We are committed to being the premier program in the Southeast, providing exceptional, state-of-the-art care to patients undergoing acute leukemia treatment, CAR T-cell immunotherapy, and blood and marrow stem cell transplantation. New patient brochure
The Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP) announce new 2025 allogeneic survival data: Northside BMT has overperformed one-year allogeneic survival outcomes for seventeen consecutive years.
NH-BMT is the ONLY BMT program in the country and the ONLY BMT program in Georgia to have achieved survival outcomes that significantly exceed the expected one-year survival rate for allogeneic and unrelated donor transplants for the last 17 consecutive reporting cycles (2009–2025) and is one of only 8 national centers (less than 2.5% of all centers) to over-perform for the current annual reporting cycle.
NH-BMT is the largest allogeneic BMT program in Georgia. To view brochure click here.
The program’s actual one-year survival rate, as reported in the December 2025 Center for International Blood and Marrow Transplant Research (CIBMTR) final 2025 Transplant Center Specific Survival Report (page 35, center 151) and nmdp.org, is 78.9%. *
For additional survival data details, visit bmtga.com/bmt-survival-data.
*Survival information includes only patients who received their first allogeneic transplant between January 1, 2021 - December 31, 2023, using unrelated or related donors and who had reported follow-up.
WSB’s radio program, Doctors on Call, interview
On April 12, 2026, WSB’s Doctors on Call radio host, Belinda Skelton, interviewed Dr. Melhem Solh, a physician at The Blood & Marrow Transplant Group of Georgia and the medical director of Northside’s Cellular Therapy Program, who described treatment updates and how our program provides leading-edge therapies for our patients.
Congratulations to Dr. Bachier and the Northside Immunotherapy Program clinical research team on their collaborative poster presentations at the 2026 ASCO and European Hematology Association annual meetings
We congratulate Dr. Bachier and the Northside Immunotherapy Program clinical research team on the presentation of their collaborative research posters at the 2026 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
We also extend our sincere appreciation to Kite, a Gilead company, and Bristol Myers Squibb for their continued partnership and support of our immunotherapy program. Through these collaborations, we can offer patients access to state-of-the-art clinical research trials and commercially available CAR T-cell therapies, helping to advance innovative treatment options and improve patient outcomes.
The first U.S. mantle cell lymphoma patient enrolled to a novel clinical trial
The Northside Hospital Cancer Institute announced its Blood & Marrow Transplant (BMT), Leukemia, and Immunotherapy Clinical Research Program has enrolled the first mantle cell lymphoma (MCL) patient nationwide in an early-phase clinical trial evaluating novel dual-target CAR T-cell therapies for patients with relapsed or refractory B-cell lymphoma.
The study, titled "A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, utilizing Kite’s DuoCore™ construct, two independent CARs working synergistically, in Subjects with Relapsed and/or Refractory B-cell Lymphoma(NCT04989803)," is sponsored by Kite, A Gilead Company. The trial is designed to evaluate the safety and efficacy of investigational autologous CAR T-cell therapies KITE-363 and KITE-753, which target both CD19 and CD20 antigens.
Northside’s Immunotherapy Program is the ONLY Center in Georgia to offer Tecelra a T-cell Therapy for Unresectable or Metastatic Synovial Sarcoma
TECELRA is a melanoma-associated antigen A4 (MAGE‑A4)-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE‑A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
TECELRA is the first single-infusion therapy that leverages the patient’s immune system to detect, target, and destroy SyS cells.
For additional information, please visit the Tecelra website at https://www.tecelra-hcp.com/
To refer a patient for consultation or speak to a Blood and Marrow Transplant Group of Georgia physician, please call 404-255-1930.
New guidelines for multiple myeloma care
Treatment for multiple myeloma is changing quickly — and that is good news for patients.
In 2019, the American Society of Clinical Oncology (ASCO) and Ontario Health jointly published evidence-based recommendations for the treatment of multiple myeloma.1 Since then, several major clinical trials have reshaped how this disease is managed.
In 2026, updated guidelines were published in the Journal of Clinical Oncology.2 The updated guidelines are based on a systematic review and were developed by a multidisciplinary expert panel, which included a patient representative and an ASCO guidelines staff member with health research methodology expertise.
Patient Stories
Jackie’s story: Her Large Cell Lymphoma journey
In April 2008, at the age of 29, I developed persistent flu and pneumonia-like symptoms. Progressive symptoms including fever, aching, lethargy, pain, my first asthma attack in 20 years, and fluid around my heart landed me in the ICU, where I remained for nearly a month! While hospitalized, I was diagnosed with Stage IV Anaplastic Large Cell Lymphoma (ALCL), situated in my lungs. Click Here to read full interview
Eva’s story: Her multiple myeloma journey
Eva Podstata of Canton is a nurse at Northside Hospital Cherokee. She is used to caring for others. But in March 2021, she became the patient after she began experiencing persistent hip pain. At 59, she attributed it to “old age.”
The pain became so severe, Eva said, that it took all she had just to walk to her office each day. Click Here to read full interview
Dawn’s story: Living with GVHD
Dawn Goodfriend, of Lawrenceville, Georgia, said she’d never been in the hospital except for a tonsillectomy in 1969. That all changed in January 2020, when she was diagnosed with acute lymphoblastic leukemia (ALL) and began treatment through the Blood and Marrow Transplant (BMT) Program at Northside Hospital. After a life-saving stem cell transplant, Dawn developed graft-versus-host disease...Click Here to read full interview
April’s story: Strength, survival and purpose after cancer
In March 2014, after nearly three months of worsening symptoms and extensive testing, April Byrd of Douglasville was diagnosed with stage 3 non-Hodgkin’s lymphoma.
Her journey began with a series of visits to her dermatologist for treatment for recurrent cysts. She would later also experience chest pain... Click Here to read full interview
